Technical Analysis for FLXN - Flexion Therapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
FLXN closed up 4.24 percent on Wednesday, February 21, 2018, on 1.54 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
|Weak or Absent||Up||Up||Up|
|See historical FLXN trend table...|
|Date||Alert Name||Type||% Chg|
|Feb 21||Crossed Above 50 DMA||Bullish||0.00%|
|Feb 21||Wide Bands||Range Expansion||0.00%|
|Feb 21||Overbought Stochastic||Strength||0.00%|
|Feb 21||Upper Bollinger Band Touch||Strength||0.00%|
|Feb 20||50 DMA Resistance||Bearish||4.24%|
|Feb 20||Wide Bands||Range Expansion||4.24%|
|Feb 16||Fell Below 50 DMA||Bearish||5.99%|
|Feb 16||Wide Bands||Range Expansion||5.99%|
|Feb 15||Crossed Above 50 DMA||Bullish||0.00%|
|Feb 15||Stochastic Reached Overbought||Strength||0.00%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Flexion Therapeutics, Inc. focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. Its lead product candidate includes FX006, an intra-articular, sustained-release triamcinolone acetonide, which has completed a Phase 2b dose-ranging clinical trial to treat moderate to severe osteoarthritis (OA) pain. The company is also developing FX007, a preclinical, small-molecule TrkA receptor antagonist to address post-operative pain; and FX005, an intra-articular, sustained-release p38 MAP kinase inhibitor, which has completed a Phase 2a clinical trial to treat end-stage OA patients. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more FLXN news...
|52 Week High||32.25|
|52 Week Low||16.51|
|200-Day Moving Average||22.9237|
|50-Day Moving Average||24.3152|
|20-Day Moving Average||23.2565|
|10-Day Moving Average||23.488|
|Average True Range||1.3992|
|Chandelier Exit (Long, 3 ATRs )||21.2024|
|Chandelier Exit (Short, 3 ATRs )||24.8776|
|Upper Bollinger Band||24.9279|
|Lower Bollinger Band||21.5851|
|Percent B (%b)||0.9|
|MACD Signal Line||-0.287|
|Market Cap||784.23 Million|
|Num Shares||31.9 Million|
|Price-to-Earnings (P/E) Ratio||-7.90|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||27.28|
|Resistance 3 (R3)||27.25||26.33||26.83|
|Resistance 2 (R2)||26.33||25.64||26.34||26.68|
|Resistance 1 (R1)||25.45||25.21||25.89||25.48||26.53|
|Support 1 (S1)||23.65||23.84||24.09||23.68||22.63|
|Support 2 (S2)||22.73||23.41||22.74||22.48|
|Support 3 (S3)||21.85||22.73||22.33|
|Support 4 (S4)||21.88|